Targeted Strategies for Today's Evolving Markets

MissionIR Blog

International Stem Cell Corp. (ISCO) Posts Key Business Highlights, Opens its Books for Q3, YtD 2015

International Stem Cell Corp. this morning posted a business update along with operating results for the three- and nine-month periods ended September 30, 2105. Among other results, the California-based biotech company reported an increase in quarterly revenues, along with significantly narrowed third-quarter and nine-month losses.

“Overall I am satisfied with the company’s progress in Q3. We are maintaining our position as a leader in regenerative medicine field and the overall operating income of our biomedical businesses continues to grow,” Andrey Semechkin, Ph.D., CEO and co-chairman of ISCO, stated in the news release. “We really look forward to beginning the enrolment of patients in our pending Parkinson’s disease clinical trial before the end of 2015.”

Q3 Business Highlights

Among several quarterly business highlights, ISCO in the third quarter of 2015 developed an innovative technology designed to generate functional articular cartilage from the patient’s own skin or adipose tissue with the potential to treat osteoarthritis. The company also moved into the second phase of its existing research agreement with global Japanese pharmaceutical company Rohto Pharmaceutical Co., Ltd.; appointed a new chief executive officer; and presented comprehensive findings from Parkinson’s disease program at the Society for Neuroscience Annual Meeting, Neuroscience 2015.

In regards to its wholly owned subsidiary, ISCO in the third quarter completed clinical testing of a new compound, which the company intends to utilize in substantially new skin care products to be marketed by its subsidiary Lifeline Skin Care, Inc., starting December 2015. Lifeline Skin Care launched its ProPlus+ professional line of products that will be available exclusively through Lifeline’s network of dermatologists, aestheticians and med spas.

Q3, YtD Financial Results

For the quarter ended in September 2015, ISCO reported revenues of $2.14 million, an increase of 9% over revenue of $173,000 posted in the third quarter of 2014. The company’s Lifeline Cell Technology sales increased by 22%, or $220,000, while Lifeline Skin Care sales decreased by 5%, or $47,000; both wholly owned subsidiaries remain profitable. ISCO’s consolidated net loss for the quarter was $539,000 compared to consolidated net loss of $2.0 million for the third quarter last year.

Total consolidated revenue for the nine months ended September 30, 2015, was $5.57 million, an increase of 7%, or $373,000, vs $5.20 million in revenue reported for the comparable period of 2014. Lifeline Cell Technology sales increased by 9%, or $244,000, while Lifeline Skin Care sales decreased by 5%, or $129,000. ISCO’s consolidated net loss for the nine months ended September 30, 2015, was $1.1 million vs a consolidated net loss of $7.9 million for the comparable nine months of last year, which the company partially attributes to the completion of multiple preclinical studies during the first six months of 2015.

ISCO ended the third quarter of 2015 with cash balance of $599,000. As of September 30, 2015, stockholders’ equity totaled $834,000.

Using its core technology, which results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs), ISCO is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (

For more information visit at

This entry was posted in International Stem Cell Corp. ISCO. Bookmark the permalink.

Comments are closed.